These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 22426819

  • 1. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Imai Y, Yoshimori M, Fukuda K, Yamagishi H, Ueda Y.
    Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
    [Abstract] [Full Text] [Related]

  • 2. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S.
    Cancer Res; 2005 Feb 15; 65(4):1541-6. PubMed ID: 15735043
    [Abstract] [Full Text] [Related]

  • 3. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S.
    Int J Cancer; 2004 Jan 01; 108(1):146-51. PubMed ID: 14618629
    [Abstract] [Full Text] [Related]

  • 4. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A, Wiese M.
    ChemMedChem; 2012 Apr 01; 7(4):650-62. PubMed ID: 22354538
    [Abstract] [Full Text] [Related]

  • 5. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
    Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, Scheffer GL, Maliepaard M, Ross DD, Bible KC, Kaufmann SH.
    Cancer Res; 2001 Jan 15; 61(2):739-48. PubMed ID: 11212277
    [Abstract] [Full Text] [Related]

  • 6. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.
    Zhang W, Ding W, Chen Y, Feng M, Ouyang Y, Yu Y, He Z.
    Acta Biochim Biophys Sin (Shanghai); 2011 Aug 15; 43(8):647-53. PubMed ID: 21712253
    [Abstract] [Full Text] [Related]

  • 7. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Nagashima S, Soda H, Oka M, Kitazaki T, Shiozawa K, Nakamura Y, Takemura M, Yabuuchi H, Fukuda M, Tsukamoto K, Kohno S.
    Cancer Chemother Pharmacol; 2006 Nov 15; 58(5):594-600. PubMed ID: 16520985
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Expression and functional analyses of breast cancer resistance protein in lung cancer.
    Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J, Nakamura Y, Doi S, Kitazaki T, Sugahara K, Yamada Y, Kamihira S, Kohno S.
    Clin Cancer Res; 2003 Aug 01; 9(8):3052-7. PubMed ID: 12912956
    [Abstract] [Full Text] [Related]

  • 10. Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
    Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y.
    Mol Cancer Ther; 2004 Sep 01; 3(9):1119-25. PubMed ID: 15367706
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW.
    Cancer Lett; 2009 Jun 28; 279(1):74-83. PubMed ID: 19232821
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma.
    Wang L, Lin N, Li Y.
    Oncol Rep; 2019 Mar 28; 41(3):1678-1690. PubMed ID: 30664164
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.